Biopharmaceutical companies increasingly deploy advanced manufacturing technologies, including automated control strategies, robotics and digital twins, across development and commercial operations. For senior leaders, the challenge emerges when these technologies are scaled beyond a single site, where uneven adoption can dilute value, increase transfer risk and slow network performance.  

The limitation is rarely the technology itself, but how organizations align platforms, facility concepts and control strategies across networks. Fragmentation in these areas introduces friction as processes move across global operations, with solutions that work well in one location often requiring extensive adaptation elsewhere. Over time, this turns technology transfer and scale-up into repeated, resource-intensive efforts rather than predictable operations. 

Addressing this challenge requires more than incremental optimization. It requires a shared industry view of how manufacturing operations must evolve, paired with a practical way to translate long-term ambition into site-level decisions. To meet this need, the BioPhorum Technology Strategy created a unified, pre-competitive environment where industry leaders collaborate to define and align future manufacturing capabilities. A foundational outcome of this work is the Future Manufacturing Operations (FMO) matrix, a planning framework designed to turn strategic intent into structured execution. 

While the industry has long had high-level technology trajectories, it lacked a practical, standardized blueprint to translate those visions into site-specific execution. The FMO matrix fills this gap by providing a foundational framework developed by more than 70 industry innovators, spanning biomanufacturers, suppliers and integrators. 

By establishing a common language for the first time, companies can  coordinate progress against a shared industry vision. This initiative provides tools and insights across both traditional biologics and emerging modalities such as advanced therapy medicinal products (ATMPs). This vision enables flexible, resilient and sustainable end-to-end biomanufacturing by focusing on four primary pillars: 

• Plant: enabling rapid changeover of multiple product modalities, lights-out manufacturing and a resilient, optimized supply chain

• Process: remaining agile, scalable and adaptive through self-improving and deviation-free platforms designed for real-time release

• People: continuously sharing and applying multi-disciplinary, innovative knowledge across a diverse, equitable and inclusive organization

• Planet: supporting the future of the planet by having no negative impact on people or the environment. 

Together, these pillars describe the end state the industry is working toward, supported by complementary dimensions captured within the broader matrix. 

A shared roadmap helps companies replace subjective planning with a consensus-based approach grounded in industry alignment. Through the FMO matrix, companies can perform benchmarking and gap analysis to identify where they sit across five maturity levels, ranging from largely site-specific, manually driven operations through to highly integrated, digitally enabled and increasingly autonomous manufacturing environments. This provides a standardized scale to measure a facility’s journey and map a clear path toward disruptive end states such as lights-out manufacturing. 

Furthermore, the framework supports informed investment decisions by providing an objective basis for prioritization, which gives suppliers concrete confidence in the industry’s future direction and helps biomanufacturers justify business cases for new technology adoption. This shared reference point reduces uncertainty for manufacturers, suppliers and partners, giving decision-makers greater  confidence that today’s investments will remain relevant as operations evolve. 

By taking this approach, aligning site-specific decisions with industry-recognized goals protects companies against rapid obsolescence while delivering measurable value at every stage of the lifecycle. By translating high-level intent into a structured path, the matrix establishes technology adoption as a core strategic asset. 

While the FMO matrix provides the strategic map, BioPhorum’s interlinked workstreams provide the technical tools required to navigate it. The four pillars articulate the long-term vision for future manufacturing, while the matrix itself applies a more granular set of five dimensions, product, plant, process, people and external linkages, to support practical assessment and execution at site and network level. 

These interlinked initiatives form a connected innovation ecosystem that supports progression toward more autonomous and adaptive manufacturing. Rather than advancing individual technologies in isolation, the work focuses on aligning foundational capabilities so that progress in one area reinforces another. 

A central outcome of this alignment is the move toward autonomous bioprocessing control (ABC), which integrates artificial intelligence (AI), machine learning and hybrid modeling to enable higher levels of automation and reduced variability across the process lifecycle. 

However, achieving autonomous control requires specific precursors. A key requirement is the implementation of digital twins, which are defined as key enablers for ABC because they provide the predictive insights and simulation capabilities required across the full drug product lifecycle. These capabilities are further underpinned by a future-facing control strategy designed to support more efficient regulatory file submissions, acting as another essential enabler of the ABC framework. 

Alongside the forthcoming digital technology transfer playbook, which aims to harmonize inter-company transfers, these workstreams are helping reduce friction as processes move across organizational boundaries. In parallel, efforts to improve the scalability of process analytical technology (PAT) are enabling more consistent, data-driven control as operations expand, together laying the foundation for more intelligent and adaptive biomanufacturing. By aligning these distinct elements, the industry can make tangible progress toward more autonomous, lights-out manufacturing.

When organizations align on shared technical enablers, the impact is reflected not only in future capability, but also in day-to-day manufacturing performance. This collaborative approach leads to measurable improvements across the core business drivers, as reflected in reported case examples and modeled outcomes: 

• Value: on-demand manufacture, applied in place of traditional buffer preparation, has been shown to reduce manufacturing costs by >60%

• Speed: best-practice approaches for detecting adventitious agents using rapid methods can shorten virus testing timelines by >90%

• Quality: digital technology transfer can reduce errors and batch failures, with reported annual savings of approximately $9.5M

• Agility: integrated digital twins have supported faster technology transfer and decision-making, with potential savings of up to $16.5M per year. 

The challenges of fragmentation are too complex for any single organization to resolve alone. Shared frameworks and pre-competitive alignment reduce duplication and increase certainty during technology adoption. The FMO matrix functions as a structured guide to transformation, supporting manufacturers in achieving greater confidence and efficiency in their operations.